Patents by Inventor Divyakant S. Desai
Divyakant S. Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9358207Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: GrantFiled: July 10, 2013Date of Patent: June 7, 2016Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Sanjeev H. Kothari, Divyakant S. Desai
-
Patent number: 9339472Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: GrantFiled: January 8, 2014Date of Patent: May 17, 2016Assignee: AstraZeneca ABInventors: Divyakant S. Desai, Bing V. Li
-
Publication number: 20140255486Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: ApplicationFiled: May 22, 2014Publication date: September 11, 2014Applicant: AstraZeneca ABInventors: Divyakant S. Desai, Bing V. LI
-
Publication number: 20140120163Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: ApplicationFiled: January 8, 2014Publication date: May 1, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Divyakant S. Desai, Bing V. Li
-
Publication number: 20140079778Abstract: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin crosslinking) during the manufacturing process and/or during shelf-life storage.Type: ApplicationFiled: January 31, 2012Publication date: March 20, 2014Applicants: AstraZeneca UK Limited, Bristol-Myers Squibb CompanyInventors: Ajit Narang, Venkatramana M. Rao, Divyakant S. Desai
-
Patent number: 8628799Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: GrantFiled: April 26, 2011Date of Patent: January 14, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Divyakant S. Desai, Bing V. Li
-
Publication number: 20130296337Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: ApplicationFiled: July 10, 2013Publication date: November 7, 2013Inventors: Sanjeev H. Kothari, Divyakant S. Desai
-
Publication number: 20130224296Abstract: The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin cross-linking) during the manufacturing process and/or during shelf-life storage.Type: ApplicationFiled: September 1, 2011Publication date: August 29, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Ajit Narang, Venkatramana M. Rao, Divyakant S. Desai
-
Patent number: 8518421Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: GrantFiled: May 16, 2011Date of Patent: August 27, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Sanjeev H. Kothari, Divyakant S. Desai
-
Publication number: 20110200672Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: ApplicationFiled: April 26, 2011Publication date: August 18, 2011Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Divyakant S. Desai, Bing V. Li
-
Patent number: 7951400Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.Type: GrantFiled: May 25, 2005Date of Patent: May 31, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Divyakant S. Desai, Bing V. Li
-
Publication number: 20100016448Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.Type: ApplicationFiled: September 14, 2009Publication date: January 21, 2010Inventors: SANJEEV KOTHARI, DIVYAKANT S. DESAI
-
Patent number: 7507768Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.Type: GrantFiled: January 30, 2007Date of Patent: March 24, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Danping Li, Lawan Phusanti, Divyakant S. Desai
-
Patent number: 7183321Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.Type: GrantFiled: December 17, 2001Date of Patent: February 27, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Danping Li, Lawan Phusanti, Divyakant S. Desai
-
Publication number: 20030139461Abstract: An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the metformin is compressible, if necessary. A method for treating diabetes is also provided employing the above formulation.Type: ApplicationFiled: December 17, 2001Publication date: July 24, 2003Inventors: Danping Li, Lawan Phusanti, Divyakant S. Desai
-
Patent number: 5994348Abstract: Pharmaceutical compositions containing irbesartan, alone or in combination with a diuretic, providing tablets with a high relative amount of active agent and excellent wetting and disintegration properties.Type: GrantFiled: May 20, 1998Date of Patent: November 30, 1999Assignee: SanofiInventors: Cathy C. Ku, Omar L. Sprockel, Beth A. Lang, Divyakant S. Desai
-
Patent number: 5801220Abstract: A rapid disintegrating and dispersing composition for thickening liquid waste into a thixotropic gel comprises a polymeric acrylic resin and a colloid-forming mixture of microcrystalline cellulose and sodium carboxymethylcellulose. Additional ingredients preferably used in making a tableted form of the composition include microcrystalline cellulose per se, polyvinylpolypyrrolidone, magnesium stearate and amorphous silica. The tablet is placed in suitable containment means such as a containment bag. The thixotropic properties of the composition enable the gelled waste to be restored to a liquid when small amounts of hand pressure are applied to the waste containment bag, thereby providing a convenient and simple means for disposal.Type: GrantFiled: November 1, 1995Date of Patent: September 1, 1998Assignee: E.R. Squibb & Sons, Inc.Inventors: Divyakant S. Desai, Ajit B. Thakur